Abstract: The present disclosure provides an article including an isoporous membrane disposed on a porous substrate. The iso-porous membrane includes a triblock copolymer or a pentablock copolymer. The isoporous membrane has a thickness and is isoporous throughout its thickness. A method of making an article is also provided, which does not require a solvent exchange process. The method includes depositing a composition on a porous substrate, thereby forming a fdm, and removing at least a portion of the solvent from the film, thereby forming an isoporous membrane having numerous pores. The composition contains a solvent and solids including a triblock copolymer or a pentablock copolymer. The article advantageously can be hydrophilic and provides sharp molecular weight cut-offs and high flux.

Abstract: A prodrug that has a prodrug moiety that degrades into a compound having the general Formula I with R3 being an alcoholic moiety can be useful in therapies for neurodegenerative diseases as well as cancer. Accordingly, the prodrug compounds can have a structure of Formula I, analogs thereof, derivatives thereof, or salts thereof, wherein: A and B are sulfur or oxygen; R1 and R2, in para, meta, or ortho position, are independently halogen, alkyl, alkoxy, haloalkyl, where R1 and R2 independently are straight chain, branched, substituted or unsubstituted; and R3 is a prodrug moiety. As examples, the prodrug can have a structure of any of Formulas I-V, which as shown in the specification.

Abstract: A prodrug that has a prodrug moiety that degrades into a compound having the general Formula I with R3 being an alcoholic moiety can be useful in therapies for neurodegenerative diseases as well as cancer. Accordingly, the prodrug compounds can have a structure of Formula I, analogs thereof, derivatives thereof, or salts thereof, wherein: A and B are sulfur or oxygen; R1 and R2, in para, meta, or ortho position, are independently halogen, alkyl, alkoxy, haloalkyl, where R1 and R2 independently are straight chain, branched, substituted or unsubstituted; and R3 is a prodrug moiety. As examples, the prodrug can have a structure of any of Formulas I-V, which as shown in the specification.

Abstract: The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states.

Abstract: An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection, and is bioequivalent with currently approved formulations. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether &bgr;-cyclodextrin) to form a true aqueous solution. This formulation minimizes the allergic response and microbial contamination issues typically associated with parenteral emulsion formulations. The present formulation also reduces pain on injection as compared to the known organic solvent based formulations containing etomidate. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.